Literature DB >> 10704809

Physical stability and in-vitro gene expression efficiency of nebulised lipid-peptide-DNA complexes.

J C Birchall1, I W Kellaway, M Gumbleton.   

Abstract

The lower respiratory tract provides a number of disease targets for gene therapy. Nebulisation is the most practical system for the aerosolisation of non-viral gene delivery systems. The aerosolisation process represents a significant challenge to the maintenance of the physical stability and biological activity of the gene vector. In this study we investigate the role of a condensing polycationic peptide on the stability and efficiency of nebulised lipid-DNA complexes. Complexes prepared from the cationic lipid 1, 2-dioleoyl-3-trimethylammonium propane (DOTAP) and plasmid DNA (pDNA) at mass (w/w) ratios of 12:1, 6:1 and 3:1, and complexes prepared from DOTAP, the polycationic peptide, protamine, and pDNA (LPD) at 3:2:1 w/w ratio were nebulised using a Pari LC Plus jet nebuliser. Samples from the nebuliser reservoir (pre- and post-nebulisation) and from the aerosol mist were collected and investigated for changes, including: particle diameter, retention of in-vitro transfection activity and the relative concentration and nature of the complexed pDNA remaining after the nebulisation procedure. The process of jet nebulisation adversely affected the physical stability of lipid:pDNA complexes with only those formulated at 12:1 w/w DOTAP:pDNA able to maintain their pre-nebulisation particle size distribution (145+/-3 nm pre-nebulisation vs. 142+/-2 nm aerosol mist) and preserve significant pDNA integrity in the reservoir (35% of pre-nebulisation pDNA band intensity). The LPD complexes were smaller (102+/-1 nm pre-nebulisation vs. 113+/-2 nm aerosol mist) with considerably greater retention of pDNA integrity in the reservoir (90% of pre-nebulisation pDNA band intensity). In contrast the concentration of pDNA in the aerosol mist for both the 12:1 w/w DOTAP:pDNA and LPD complexes were significantly reduced (10 and 12% of pre-nebulised values, respectively). Despite reduced pDNA concentration the transfection (% cells transfected) mediated by aerosol mist for the nebulised complexes was comparatively efficient (LPD aerosol mist 26 vs. 40% for pre-nebulised complex; the respective values for 12: 1 w/w DOTAP:pDNA were 12 vs. 28%). The physical stability and biological activity of nebulised lipid:pDNA complexes can be improved by inclusion of a condensing polycationic peptide such as protamine. The incorporation of the peptide precludes the use of potentially toxic excesses of lipid and charge and may act as a platform for the covalent attachment of peptide signals mediating sub-cellular targetting.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10704809     DOI: 10.1016/s0378-5173(00)00339-2

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  10 in total

1.  Transfection efficiency of pORF lacZ plasmid lipopolyplex to hepatocytes and hepatoma cells.

Authors:  Xun Sun; Hong-Wei Zhang; Zhi-Rong Zhang
Journal:  World J Gastroenterol       Date:  2004-02-15       Impact factor: 5.742

2.  Gene delivery to the epidermal cells of human skin explants using microfabricated microneedles and hydrogel formulations.

Authors:  Marc Pearton; Chris Allender; Keith Brain; Alexander Anstey; Chris Gateley; Nicolle Wilke; Anthony Morrissey; James Birchall
Journal:  Pharm Res       Date:  2007-08-02       Impact factor: 4.200

3.  Delivery of pDNA Polyplexes to Bronchial and Alveolar Epithelial Cells Using a Mesh Nebulizer.

Authors:  Larissa Gomes Dos Reis; Maree Svolos; Lyn M Moir; Rima Jaber; Norbert Windhab; Paul M Young; Daniela Traini
Journal:  Pharm Res       Date:  2018-11-15       Impact factor: 4.200

4.  Development of an ex vivo human skin model for intradermal vaccination: tissue viability and Langerhans cell behaviour.

Authors:  Keng Wooi Ng; Marc Pearton; Sion Coulman; Alexander Anstey; Christopher Gateley; Anthony Morrissey; Christopher Allender; James Birchall
Journal:  Vaccine       Date:  2009-08-11       Impact factor: 3.641

5.  Nebulisation of receptor-targeted nanocomplexes for gene delivery to the airway epithelium.

Authors:  Maria D I Manunta; Robin J McAnulty; Aristides D Tagalakis; Stephen E Bottoms; Frederick Campbell; Helen C Hailes; Alethea B Tabor; Geoffrey J Laurent; Christopher O'Callaghan; Stephen L Hart
Journal:  PLoS One       Date:  2011-10-26       Impact factor: 3.240

6.  Nebulisation of IVT mRNA Complexes for Intrapulmonary Administration.

Authors:  Sarah M Johler; Joanna Rejman; Shan Guan; Joseph Rosenecker
Journal:  PLoS One       Date:  2015-09-09       Impact factor: 3.240

7.  Intratracheal Administration of siRNA Dry Powder Targeting Vascular Endothelial Growth Factor Inhibits Lung Tumor Growth in Mice.

Authors:  Kei Miwata; Hirokazu Okamoto; Taku Nakashima; Daisuke Ihara; Yasushi Horimasu; Takeshi Masuda; Shintaro Miyamoto; Hiroshi Iwamoto; Kazunori Fujitaka; Hironobu Hamada; Ayumi Shibata; Takaaki Ito; Tomoyuki Okuda; Noboru Hattori
Journal:  Mol Ther Nucleic Acids       Date:  2018-07-17       Impact factor: 8.886

Review 8.  siRNA Therapeutics against Respiratory Viral Infections-What Have We Learned for Potential COVID-19 Therapies?

Authors:  Aditi Mehta; Thomas Michler; Olivia M Merkel
Journal:  Adv Healthc Mater       Date:  2021-01-27       Impact factor: 11.092

9.  Effective pulmonary delivery of an aerosolized plasmid DNA vaccine via surface acoustic wave nebulization.

Authors:  Anushi E Rajapaksa; Jenny J Ho; Aisha Qi; Rob Bischof; Tri-Hung Nguyen; Michelle Tate; David Piedrafita; Michelle P McIntosh; Leslie Y Yeo; Els Meeusen; Ross L Coppel; James R Friend
Journal:  Respir Res       Date:  2014-05-20

Review 10.  Nanotechnologies in Delivery of DNA and mRNA Vaccines to the Nasal and Pulmonary Mucosa.

Authors:  Jie Tang; Larry Cai; Chuanfei Xu; Si Sun; Yuheng Liu; Joseph Rosenecker; Shan Guan
Journal:  Nanomaterials (Basel)       Date:  2022-01-11       Impact factor: 5.076

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.